R788 disodium salt
| Code | Size | Price |
|---|
| SYN-1122-M100 | 100 mg | Enquire |
Quantity:
| SYN-1122-M001 | 1 mg | £133.00 |
Quantity:
| SYN-1122-M005 | 5 mg | £203.00 |
Quantity:
| SYN-1122-M010 | 10 mg | £361.00 |
Quantity:
| SYN-1122-M050 | 50 mg | £1,146.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
Fostamatinib; Tamatinib fosdium; FosD; R-788
Appearance:
Solid.
CAS:
1025687-58-4
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C23H26FN6O9P.2Na/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4;;/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29);;/q;2*+1/p-2
InChiKey:
HSYBQXDGYCYSGA-UHFFFAOYSA-L
Long Description:
Chemical. CAS: 1025687-58-4. Formula: C23H24FN6O9P . 2Na. MW: 578.5 . 46.0. Tamatinib effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolonged survival of the treated animals.
Molecular Formula:
C23H24FN6O9P . 2Na
Molecular Weight:
578.5 . 46.0
Package Type:
Plastic Vial
Product Description:
Tamatinib effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B cells and significantly prolonged survival of the treated animals.
Purity:
>95%
Solubility Chemicals:
Slightly soluble (<1mg/ml) in DMSO or ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Rational design of highly selective spleen tyrosine kinase inhibitors: M.C. Lucas, et al.; J. Med. Chem. 55, 10414 (2012)
Related Products
| Product Name | Product Code | Supplier | Nilotinib | SYN-1057 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|